Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Severe and Critical COVID-19 with Refractory Hypoxia
NCT05689008Phase 3Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human umbilical cord mesenchymal stem cells in COVID-19 pneumonia (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Oxygenation index (PaO2/FiO2) at 28 days. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05689008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689008.